Related resources
Full-text held externally
Search for item elsewhere
University researcher(s)
Evidence-based recommendations for the use of antiemetics in radiotherapy
Maranzano E, Feyer P, Molassiotis A, Rossi R, Clark-Snow R, Olver I, Warr D, Schiavone C, Roila F
Radiotherapy and Oncology. 2005;76.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
Abstract
Background and purpose: To report recommendations given in the Multinational Association of Supportive Care in Cancer (MASCC) International Consensus Conference regarding the use of antiemetics in radiotherapy.Patients and methods: A steering committee under MASCC auspice chose panel participants for the guidelines development process on prevention of chemotherapy- and radiotherapy-induced emesis (RIE). Pertinent information from published literature as of March 2004 was reviewed for the guideline process. Both the MASCC level of scientific confidence and level of consensus, and the American Society of Clinical Oncology (ASCO) type of evidence and grade for recommendation were adopted.Results: Total body irradiation is classified as high risk, upper abdomen at moderate, lower thorax, pelvis, cranium (radiosurgery) and craniospinal at low, head and neck, extremities, cranium and breast at minimal risk. The recommendations for the use of antiemetics in radiotherapy are as follows: prophylaxis or rescue with a patients at high and moderate risk levels of RIE(± dexamethasone in the former group), prophylaxis